Title and abstract 1* How participants were allocated to interventions (eg, "random allocation," "randomized," or "randomly assigned"), specifying that the trial is a noninferiority or equivalence trial.
INTRODUCTION

Background
2* Scientific background and explanation of rationale, including the rationale for using a noninferiority or equivalence design.
3-5
METHODS
Participants
3*
Eligibility criteria for participants (detailing whether participants in the noninferiority or equivalence trial are similar to those in any trial [s] that established efficacy of the reference treatment) and the settings and locations where the data were collected.
5-6
Interventions 4* Precise details of the interventions intended for each group, detailing whether the reference treatment in the noninferiority or equivalence trial is identical (or very similar) to that in any trial(s) that established efficacy, and how and when they were actually administered.
7-8
Objectives 5* Specific objectives and hypotheses, including the hypothesis concerning noninferiority or equivalence.
5-6
Outcomes 6* Clearly defined primary and secondary outcome measures, detailing whether the outcomes in the noninferiority or equivalence trial are identical (or very similar) to those in any trial(s) that established efficacy of the reference treatment and, when applicable, any methods used to enhance the quality of measurements (eg, multiple observations, training of assessors).
7
Sample size 7* How sample size was determined, detailing whether it was calculated using a noninferiority or equivalence criterion and specifying the margin of equivalence with the rationale for its choice. When applicable, explanation of any interim analyses and stopping rules (and whether related to a noninferiority or equivalence hypothesis).
7-8
Randomization Sequence generation 8 Method used to generate the random allocation sequence, including details of any restriction (eg, blocking, stratification).
Allocation concealment
9 Method used to implement the random allocation sequence (eg, numbered containers or central telephone), clarifying whether the sequence was concealed 7 Implementation 10 Who generated the allocation sequence, who enrolled participants, and who assigned participants to their groups. 7 Blinding (masking) 11 Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to group assignment. When relevant, how the success of blinding was evaluated.
7
Statistical methods 12* Statistical methods used to compare groups for primary outcome(s), specifying whether a 1-or 2-sided confidence interval approach was used. Methods for additional analyses, such as subgroup analyses and adjusted analyses.
8
Results
Participant flow 13 Flow of participants through each stage (a diagram is strongly recommended).
Specifically, for each group report the numbers of participants randomly assigned, receiving intended treatment, completing the trial protocol, and analyzed for the primary outcome. Describe protocol deviations from trial as planned, together with 17 Recruitment 14 Dates defining the periods of recruitment and follow-up. 7 Baseline data 15 Baseline demographic and clinical characteristics of each group. 19 Numbers analyzed 16* Number of participants (denominator) in each group included in each analysis and whether "intention-to-treat" and/or alternative analyses were conducted. State the results in absolute numbers when feasible (eg, 10/20, not 50%).
Fig 1
Outcomes and estimation 17* For each primary and secondary outcome, a summary of results for each group and the estimated effect size and its precision (eg, 95% confidence interval). For the outcome(s) for which noninferiority or equivalence is hypothesized, a figure showing confidence intervals and margins of equivalence may be useful.
21
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including subgroup analyses and adjusted analyses, indicating those prespecified and those exploratory.
Adverse events 19 All important adverse events or side effects in each intervention group.
